Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cortexin effectiveness in circulatory encephalopathy].

V Kh Khavinson, V G Morozov, V Iu Rybnikov

    Klinicheskaia Meditsina
    |June 5, 1999
    PubMed
    Summary

    Cortexin, a peptide bioregulator, enhanced rehabilitation for dyscirculatory encephalopathy (DE) by 22.7%. This treatment improved cognitive functions and neurological status with no reported side effects in patients with DE stages I-II.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Stage I cholelithiasis. Approaches to diagnosis and treatment. Results of the Machaon study].

    Terapevticheskii arkhiv·2025
    Same author

    [The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases].

    Terapevticheskii arkhiv·2022
    Same author

    [Hemorrhagic fever with renal syndrome group outbreak caused by Sochi virus.]

    Voprosy virusologii·2019
    Same author

    [Audiodiagnostics in examination of patients with internal TMJ derangement].

    Stomatologiia·2015
    Same author

    [Actual problems of hemorrhagic fever with renal syndrome].

    Zhurnal mikrobiologii, epidemiologii i immunobiologii·2013
    Same author

    Propagation of curved activation fronts in anisotropic excitable media.

    Journal of biological physics·2013

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Clinical Medicine

    Background:

    • Dyscirculatory encephalopathy (DE) involves impaired cerebral circulation affecting cognitive and neurological functions.
    • Current standard therapies for DE offer limited efficacy in restoring full function.
    • Peptide bioregulators represent a novel therapeutic approach for neurological disorders.

    Purpose of the Study:

    • To evaluate the efficacy of cortexin, a novel peptide bioregulator, as an adjuvant therapy for dyscirculatory encephalopathy (DE) stages I-II.
    • To assess the impact of cortexin delivered via nasal electrophoresis (NE) on clinical symptoms and neurocognitive functions in DE patients.
    • To determine the overall improvement in rehabilitation efficiency when cortexin is added to standard DE treatment.

    Main Methods:

    Related Experiment Videos

    • A clinical trial involving 76 patients diagnosed with DE stages I-II.
    • Patients were randomized into a control group (standard therapy) and a study group (standard therapy + cortexin via NE).
    • Efficacy was assessed using clinical evaluations, psychophysiological tests, computed electroencephalography (EEG), and quantitative rehabilitation metrics.

    Main Results:

    • Cortexin nasal electrophoresis (NE) significantly improved psychoemotional state, neurological status, and intellectual-mnestic functions.
    • Adjuvant cortexin therapy increased rehabilitation efficiency in DE stages I and II by 22.7%.
    • Improvements were most pronounced in intellectual-mnestic and central nervous system (CNS) functions, including attention, perception, memory, and thinking.

    Conclusions:

    • Cortexin demonstrates a positive therapeutic effect in patients with dyscirculatory encephalopathy (DE) stages I-II.
    • The peptide bioregulator cortexin enhances cognitive functions and neurodynamic processes.
    • Cortexin is well-tolerated, exhibits no side effects, and is recommended for combined DE treatment.